Laura Hamill - 12 Jun 2026 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Reporting relationship: Director
Issuer ticker: FATE
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 16:05:29 UTC
Prior SEC filing: 19 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Cindy Tahl, as Attorney-in-Fact

Key filing fact

Laura Hamill filed Form 4 for FATE THERAPEUTICS INC (FATE) on 15 Jun 2026.

Key facts

This page summarizes Laura Hamill's Form 4 filing for FATE THERAPEUTICS INC (FATE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 19 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001751804 Primary reporting owner

Hamill Laura

Relationship: Director
Address: C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO
Signature: /s/ Cindy Tahl, as Attorney-in-Fact
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FATE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +175,800
Change %
Price: $0.000000^*
Shares after: 175,800
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 175,800
Exercise price: $2.06
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for an equity grant upon a director's appointment or election to the Board of Directors.

Footnote F2

The shares subject to this option shall vest in 36 equal monthly installments following June 12, 2026, such that all of the shares shall be fully vested and exercisable on June 12, 2029, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.